Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

t-experienced patients with HCV genotype 1. In this study, low doses of ritonavir were used for metabolic inhibition to enhance the levels of SCH 900518 within the body and reduce the frequency of SCH 900518 dosing (BID vs. TID).

In the study, SCH 900518 administered as monotherapy exhibited potent antiviral activity, achieving 4.0-4.5 log10 decreases in viral load (HCV RNA) from baseline at day 8. SCH 900518 was well tolerated, with no drug related serious adverse events. Pharmacokinetic and pharmacodynamic modeling from this study was used to design the ongoing Phase IIa dose-finding study of SCH 900518 with ritonavir in combination with PEGINTRON and REBETOL. This study, known as NEXT-1, explores SCH 900518 in 200 mg, 400 mg or 600 mg once daily (QD) doses with low-dose ritonavir (100 mg) in combination with PEGINTRON and REBETOL (with and without a 4-week P/R lead-in period) in treatment-naive patients with HCV genotype 1.

About the HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks. In Part I of the study, the boceprevir regimens were compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). In Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL for 48 weeks was compared t
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014  Decision Resources Group is launching an extension ... to now include ChinaTrack; the new capabilities track the ... interactive dashboard providing detailed brand-level share tracking and analytics. ... level. Other key capabilities of the new ... addition to end-user surveys of healthcare facilities, ChinaTrack data ...
(Date:7/31/2014)... July 31, 2014 Hovione today announced ... has successfully passed a pre-approval inspection by the US ... out by the FDA Consumer Safety Officer, Ms. Britanny ... 21 st July and concluded on the 25 th ... the principles and guidelines of Good Manufacturing Practices (GMP) and ...
(Date:7/31/2014)... , July 31, 2014 AFFiRiS ... New York results of AFF008, a Phase I ... is the first therapy against the protein alpha-synuclein, a promising ... Michael J. Fox Foundation for Parkinson,s Research (MJFF) supported the ... the press conference on the impact a disease-modifying therapy would ...
Breaking Medicine Technology:Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... Calif. , June 3 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... will present during the Jefferies 2010 Global Life Sciences Conference.  The Alexza presentation ... ET .  The presentation will be webcast from the Grand Hyatt Hotel in ... , To ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that William Roberts ... Global Life Sciences Conference at 4:00 P.M. ET on Wednesday, ... in New York City . , ... Mr. Roberts also will present at the ThinkEquity Healthcare Conference at 1:30 ...
Cached Medicine Technology:Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference 2Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference 3ViroPharma to Participate in Two June Healthcare Investor Conferences 2
(Date:7/31/2014)... 31, 2014 Parker Waichman, LLP, a ... cases, comments that whistleblowers are a critical component of ... activities that may cause harm to consumers and may ... Whistleblower Appreciation Day. , According to a 2013 report ... Senate declared "National Whistleblower Appreciation Day" on July 30, ...
(Date:7/31/2014)... 31, 2014 Etymotic Research, an ... new sponsorship of the DrumLine Battle® series of ... hearing protection products ETY•Plugs® and Music•PRO® electronic earplugs. ... harmful effects of high-level sound. Etymotic will be ... the Drum Corps International Championships on August 7-9, ...
(Date:7/31/2014)... News) -- Many black women put concerns about their ... It,s estimated by the U.S. Centers for Disease Control ... in the United States are overweight or obese. Yet ... having to have their hair restyled or restraightened, the ... However, the researchers also noted a shift toward more ...
(Date:7/31/2014)... Rich Dad® Education , a leader ... benefit Habitat for Humanity. The yard sale was a success. ... of the proceeds donated to Habitat for Humanity of Lee ... the event were donated to the Habitat for Humanity ReStore ... Florida 33903. , Of the over $650, roughly $30 ...
(Date:7/31/2014)... an algorithm aimed to diagnose pediatric patients with ... (CT) scans, without affecting diagnostic accuracy, Mayo Clinic ... recently published in the journal Surgery . ... of acute abdominal pain in children. Appendicitis occurs ... pus. CT scans are often used to diagnose ...
Breaking Medicine News(10 mins):Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 2Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 3Health News:National Whistleblower Appreciation Day Declared to Ensure Recognition of Enormous Contribution to the Democracy by Whistleblowers, Parker Waichman LLP Comments 4Health News:Etymotic Research Becomes The Official Hearing Protection Sponsor Of DrumLine Battle 2Health News:Hairdo Trumps Exercise for Many Black Women, Study Finds 2Health News:Rich Dad Education Charity Yard Sale to Benefit Habitat for Humanity of Lee and Hendry Counties a Success 2
... announcement of the Genetics & Public Policy Center ... May 5 To "get personalized medicine right," ... need to "create and implement a reasonable and ... advanced medical diagnostics, a diverse coalition of more ...
... and cardiovascular disease in obese women, but getting started ... study by researchers at the Swedish medical university Karolinska ... more women to exercise to and from work. ... for helping populations at risk of heart disease and ...
... In support of World Asthma Day, ... partnership with Direct Relief International, a nonprofit humanitarian ... of QVAR(R) (Beclomethasone HFA), an Inhaled Corticosteroid (ICS) ... will distribute the medication to economically disadvantaged and ...
... Bates County Memorial Hospital (BCMH), a ... the MedGenix financial and patient management system. The MedGenix ... cycle management and financial accounting modules. The MedGenix ... Systems (CHS), based in Springfield, MO. Founded in 1992, ...
... goals to expand nationwide, Wellspring recently ... Bill will spearhead the newly formed Network Development Division that ... 2010. He is responsible for making Wellspring a household name ... Fortune 100 senior executive with healthcare, insurance and leading technology ...
... May 5 Air Products (NYSE: APD ... U.S. home infusion therapy services business and some elements ... OptionCare Enterprises, Inc., a subsidiary of Walgreen Co. ... Air Products, ownership interests in certain of the companies ...
Cached Medicine News:Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 2Health News:Overhaul of Genetic and Other Advanced Diagnostic Testing Regulations Necessary for Personalized Medicine, HHS Secretary Told 3Health News:Extra support helps obese women cycle to and from work 2Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 2Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 3Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 4Health News:Teva Respiratory Supports World Asthma Day by Providing FREE QVAR(R) to Those Who Need It Most 5Health News:MedGenix Financial Information System Selected by Bates County Memorial Hospital 2Health News:Wellspring Hires William Young and Prepares for Nationwide Expansion 2Health News:Air Products Sells Major Portion of U.S. Healthcare Operations to Walgreens 2
... The Leica RM2235 is a robust ... of primarily biological specimens embedded in ... backlash-free precision micrometer feed system ensures ... even when sectioning harder tissues. The ...
... biomedical and industrial applications, the Leica SM2400 ... of applications in all laboratories where paraffin ... sectioned. Its sturdy construction lends it qualities ... features of the system, such as a ...
... Automatic microtome with vibrating blade for fixed and ... as for non-biological specimen in material science ... of blade amplitude between 0,1 and 1,2 mm ... parameters can be set independently from each other. ...
... EC 350 consists of two modular units. ... surface and reaches a temperature of -15C. ... reservoir, heated dispenser nozzle, heated work surface, ... separate heated compartments for molds and cassettes. ...
Medicine Products: